Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

NVO currently markets its obesity drug Wegovy and diabetes drug Ozempic, both of which contain the active ingredient semaglutide — a direct competitor to Lilly’s tirzepatide. Shares of Viking ...

Eli Lilly plans to submit an approval review to the FDA based on the Phase 3 results for heart failure, expecting to launch it within this year. CEO Ricks said, "Tirzepatide has confirmed efficacy ...

Shares of Eli Lilly and Co. fell more than 7% in midday ... and U.S. supply across all doses of tirzepatide was available throughout Q4.” The company said the rest of its medications performed ...